

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH AN ANXIETY DISORDER

1. **Clinical practice guidelines. Management of anxiety disorders.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2006, **51**(8 Suppl 2):9s-91s.
2. **Pharmacogenomic testing for psychotropic medication selection: A systematic review of the Assurex GeneSight psychotropic test.** *Ontario health technology assessment series* 2017, **17**(4):1-39.
3. Aldrich SL, Poweleit EA, Prows CA, Martin LJ, Strawn JR, Ramsey LB: **Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders.** *Front Pharmacol* 2019, **10**:99.
4. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Glatt CE, Latoussakis V, Kelly RE, Jr., Kanellopoulos D, Klimstra S, Lim KO, Young RC *et al*: **Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression.** *Journal of affective disorders* 2009, **119**(1-3):132-141.
5. Allergan USA Inc: **Celexa (citalopram).** In: *US Product Monograph.* Madison, NJ; 2019.
6. Allergan USA Inc: **Cipralext (escitalopram).** In: *US Product Monograph.* Madison, NJ; 2019.
7. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G: **Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.** *Human psychopharmacology* 2004, **19**(6):387-396.
8. Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball S, Russell J: **A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.** *Journal of psychopharmacology (Oxford, England)* 2008, **22**(4):417-425.
9. American Psychiatric Association DSM-5 Task Force: **Diagnostic and statistical manual of mental disorders : DSM-5.** In., 5th edn. Washington, D.C.: American Psychiatric Association,; 2013: 1 online resource.
10. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI: **Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.** *The American journal of gastroenterology* 2014, **109**(6):811-819.
11. ANI Pharmaceuticals Inc: **Fluvoxamine maleate.** In: *US Product Monograph.* Baudette, MN; 2017.
12. Areberg J, Petersen KB, Chen G, Naik H: **Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals.** *Basic & clinical pharmacology & toxicology* 2014, **115**(6):552-559.

13. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: **5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study.** *Journal of clinical psychopharmacology* 2003, **23**(6):563-567.
14. Baldwin DS, Waldman S, Allgulander C: **Evidence-based pharmacological treatment of generalized anxiety disorder.** *The international journal of neuropsychopharmacology* 2011, **14**(5):697-710.
15. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N *et al*: **Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.** *Journal of psychopharmacology (Oxford, England)* 2014, **28**(5):403-439.
16. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E: **Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2007, **8**(3):175-187.
17. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar J, Hollander E, Kasper S, Moller HJ, Bandelow B *et al*: **World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2008, **9**(4):248-312.
18. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: **Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.** *The international journal of neuropsychopharmacology* 2010, **13**(3):305-320.
19. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ, Care WTFoMDiP, Wfsbp Task Force on Anxiety Disorders OCD, Ptsd: **Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.** *International journal of psychiatry in clinical practice* 2012, **16**(2):77-84.
20. Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D: **Efficacy of treatments for anxiety disorders: a meta-analysis.** *International clinical psychopharmacology* 2015, **30**(4):183-192.
21. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR: **Efficacy of olanzapine in social anxiety disorder: a pilot study.** *Journal of psychopharmacology (Oxford, England)* 2002, **16**(4):365-368.
22. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE *et al*: **Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2011, **36**(6):1219-1226.

23. BGP Pharma ULC: **Luvox (fluvoxamine)**. In: *CA Product Monograph*. Etobicoke, ON; 2017.
24. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA *et al*: **ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents**. *Journal of the American College of Cardiology* 2008, **52**(18):1502-1517.
25. Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, Choudhari P, Boberg M, Pearce RE, Gaedigk R *et al*: **Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver**. *Clinical pharmacology and therapeutics* 2019, **105**(1):131-141.
26. Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH: **Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants**. *British journal of clinical pharmacology* 2008, **65**(4):558-564.
27. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA *et al*: **Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment**. *Nat Genet* 2004, **36**(12):1319-1325.
28. Borobia AM, Novalbos J, Guerra-Lopez P, Lopez-Rodriguez R, Tabares B, Rodriguez V, Abad-Santos F, Carcas AJ: **Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers**. *Pharmacological research* 2009, **59**(6):393-398.
29. Boshuisen ML, Slaap BR, Vester-Blokland ED, den Boer JA: **The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period**. *International clinical psychopharmacology* 2001, **16**(6):363-368.
30. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T: **Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study**. *The British journal of psychiatry : the journal of mental science* 2005, **187**:352-359.
31. Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA: **Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder**. *The pharmacogenomics journal* 2014, **14**(2):176-181.
32. Brockmoller J, Meineke I, Kirchheiner J: **Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects**. *Clinical pharmacology and therapeutics* 2007, **81**(5):699-707.
33. Bystritsky A, Kerwin L, Feusner JD, Vapnik T: **A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder**. *Psychopharmacology bulletin* 2008, **41**(1):46-51.
34. Canadian Pharmacists Association: **Moclobemide [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2011.
35. Canadian Pharmacists Association: **Selective Serotonin Reuptake Inhibitors [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2014.

36. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE *et al*: **Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)**. *Genetics in medicine : official journal of the American College of Medical Genetics* 2017, **19**(2):215-223.
37. Chang M, Tybring G, Dahl ML, Lindh JD: **Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis**. *Clinical pharmacokinetics* 2014, **53**(9):801-811.
38. Charlier C, Broly F, Lhermitte M, Pinto E, Anseau M, Plomteux G: **Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine**. *Therapeutic drug monitoring* 2003, **25**(6):738-742.
39. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG: **Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers**. *Clinical pharmacology and therapeutics* 2005, **77**(6):486-494.
40. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: **Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial**. *Journal of consulting and clinical psychology* 2003, **71**(6):1058-1067.
41. College of Family Physicians of Canada: **Authorizing dried cannabis for chronic pain or anxiety: preliminary guidance from the College of Family Physicians of Canada**. Mississauga, ON; 2014.
42. Corley DA, Kubo A, Zhao W, Quesenberry C: **Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients**. *Gastroenterology* 2010, **139**(1):93-101.
43. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ: **UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver**. *The Journal of pharmacology and experimental therapeutics* 2004, **310**(2):656-665.
44. Covin R, Ouimet AJ, Seeds PM, Dozois DJ: **A meta-analysis of CBT for pathological worry among clients with GAD**. *J Anxiety Disord* 2008, **22**(1):108-116.
45. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J: **An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding**. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2009, **7**(12):1314-1321.
46. Davidson JR, DuPont RL, Hedges D, Haskins JT: **Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder**. *The Journal of clinical psychiatry* 1999, **60**(8):528-535.

47. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: **Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.** *Archives of general psychiatry* 2004, **61**(10):1005-1013.
48. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, van der Hoop RG, Li D: **Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.** *Journal of clinical psychopharmacology* 2004, **24**(2):118-125.
49. Demirbugen Oz M, Uckun Z, Yuce-Artun N, Baskak B, Ozdemir H, Kizil Ozel T, Devrimci Ozguven H, Suzen HS: **The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients.** *Human psychopharmacology* 2018, **33**(5):e2673.
50. Depping AM, Komossa K, Kissling W, Leucht S: **Second-generation antipsychotics for anxiety disorders.** *The Cochrane database of systematic reviews* 2010(12):Cd008120.
51. Donovan MR, Glue P, Kolluri S, Emir B: **Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis.** *Journal of affective disorders* 2010, **123**(1-3):9-16.
52. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
53. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J: **Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.** *Pharmacogenetics* 2003, **13**(1):39-47.
54. Eli Lilly and Company: **Cymbalta (duloxetine).** In: *US Product Monograph.* Indianapolis , IN; 2017.
55. Eli Lilly Canada Inc: **Cymbalta (duloxetine).** In: *CA Product Monograph.* Toronto, ON; 2016.
56. Eli Lilly Canada Inc: **Prozac (fluoxetine).** In: *CA Product Monograph.* Toronto, Ontario: Eli Lilly Canada Inc.,; 2016.
57. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE: **The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.** *Headache* 2010, **50**(6):1089-1099.
58. Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D *et al*: **Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2018, **28**(8):945-954.
59. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R: **Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.** *International clinical psychopharmacology* 2011, **26**(4):213-220.

60. Frech EJ, Go MF: **Treatment and chemoprevention of NSAID-associated gastrointestinal complications.** *Ther Clin Risk Manag* 2009, **5**:65-73.
61. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J: **Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.** *British journal of clinical pharmacology* 1999, **47**(4):450-453.
62. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J: **The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.** *European journal of clinical pharmacology* 2000, **56**(2):175-180.
63. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissioti A, Langstrom B, Fredrikson M: **Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy.** *Archives of general psychiatry* 2002, **59**(5):425-433.
64. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M *et al*: **Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.** *Biological psychiatry* 2005, **58**(2):132-142.
65. Gelernter CS, Uhde TW, Cimboric P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ: **Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.** *Archives of general psychiatry* 1991, **48**(10):938-945.
66. Gendep Investigators, Mars Investigators, Star D Investigators: **Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.** *The American journal of psychiatry* 2013, **170**(2):207-217.
67. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T *et al*: **Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.** *Therapeutic drug monitoring* 2003, **25**(4):463-468.
68. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T *et al*: **Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.** *Psychopharmacology* 2003, **167**(4):443-448.
69. Gillman PK: **Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review.** *Headache* 2010, **50**(2):264-272.
70. GlaxoSmithKline Inc: **Paxil (paroxetine).** In: *CA Product Monograph.* Mississauga, ON; 2016.
71. GlaxoSmithKline LLC: **Paxil (paroxetine).** In: *US Product Monograph.* Weston, FL; 2017.
72. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: **Early coadministration of clonazepam with sertraline for panic disorder.** *Archives of general psychiatry* 2001, **58**(7):681-686.

73. Goldberg MR, Lowry RC, Musson DG, Birk KL, Fisher A, De Puy ME, Shadle CR: **Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.** *Journal of clinical pharmacology* 1999, **39**(2):192-199.
74. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: **Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.** *European journal of clinical pharmacology* 2004, **60**(5):329-336.
75. Guaiana G, Barbui C, Cipriani A: **Hydroxyzine for generalised anxiety disorder.** *The Cochrane database of systematic reviews* 2010(12):Cd006815.
76. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J *et al*: **Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.** *International clinical psychopharmacology* 2007, **22**(3):167-174.
77. Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C: **Increased bioavailability of oral melatonin after fluvoxamine coadministration.** *Clinical pharmacology and therapeutics* 2000, **67**(1):1-6.
78. Haslemo T, Eliasson E, Jukic MM, Ingelman-Sundberg M, Molden E: **Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.** *British journal of clinical pharmacology* 2019, **85**(1):194-201.
79. He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, Court MH: **Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.** *British journal of clinical pharmacology* 2009, **68**(5):721-730.
80. Hedayati SS, Yalamanchili V, Finkelstein FO: **A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease.** *Kidney International* 2012, **81**(3):247-255.
81. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H: **Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.** *European journal of clinical pharmacology* 2008, **64**(5):483-487.
82. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, A LL *et al*: **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.** *Clinical pharmacology and therapeutics* 2015, **98**(2):127-134.
83. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L: **Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.** *Journal of clinical psychopharmacology* 2000, **20**(5):556-559.

84. Hofmann SG, Smits JA: **Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials.** *The Journal of clinical psychiatry* 2008, **69**(4):621-632.
85. Hofmann SG, Sawyer AT, Korte KJ, Smits JA: **Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review.** *International journal of cognitive therapy* 2009, **2**(2):160-175.
86. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB: **Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2010, **35**(3):727-740.
87. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G *et al*: **Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.** *Archives of general psychiatry* 2007, **64**(7):783-792.
88. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, Maier W, Hauser J, Souery D *et al*: **Moderation of antidepressant response by the serotonin transporter gene.** *The British journal of psychiatry : the journal of mental science* 2009, **195**(1):30-38.
89. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E, Kampman O: **5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.** *Neuroreport* 2009, **20**(12):1125-1128.
90. Illi A, Poutanen O, Setala-Soikkeli E, Kampman O, Viikki M, Huhtala H, Mononen N, Haraldsson S, Koivisto PA, Leinonen E *et al*: **Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?** *European archives of psychiatry and clinical neuroscience* 2011, **261**(2):95-102.
91. Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, Okuyama K, Tanaka E, Nakamura T, Kohda Y *et al*: **CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia.** *Clinical pharmacology and therapeutics* 2005, **78**(6):647-655.
92. Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, Saito A, Kato K, Inoue Y, Shimoda K: **Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder.** *European journal of clinical pharmacology* 2011, **67**(12):1213-1221.
93. Jaquenoud Sirot E, Harenberg S, Vandell P, Lima CA, Perrenoud P, Kemmerling K, Zullino DF, Hilleret H, Crettol S, Jonzier-Perey M *et al*: **Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression.** *Journal of clinical psychopharmacology* 2012, **32**(5):622-629.
94. Jose M, Mathaiyan J, Kattimani S, Adithan S, Chandrasekaran A: **Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.** *European journal of clinical pharmacology* 2016, **72**(7):807-812.

95. Jukic MM, Haslemo T, Molden E, Ingelman-Sundberg M: **Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients.** *The American journal of psychiatry* 2018, **175**(5):463-470.
96. Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R: **Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.** *International clinical psychopharmacology* 2009, **24**(3):119-125.
97. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B: **Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial.** *International clinical psychopharmacology* 2009, **24**(2):87-96.
98. Kasper S, Gastpar M, Muller WE, Volz HP, Moller HJ, Schlafke S, Dienel A: **Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.** *The international journal of neuropsychopharmacology* 2014, **17**(6):859-869.
99. Katoh Y, Uchida S, Kawai M, Takei N, Mori N, Kawakami J, Kagawa Y, Yamada S, Namiki N, Hashimoto H: **Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.** *Biological & pharmaceutical bulletin* 2010, **33**(2):285-288.
100. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles a, McGill U, Antony MM, Bouchard S *et al*: **Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.** *BMC psychiatry* 2014, **14** Suppl 1:S1.
101. Kawaguchi DM, Glatt SJ: **GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.** *Pharmacogenomics* 2014, **15**(11):1451-1459.
102. Kawalec P, Cierniak A, Pilc A, Nowak G: **Pregabalin for the treatment of social anxiety disorder.** *Expert opinion on investigational drugs* 2015, **24**(4):585-594.
103. Kawanishi C, Lundgren S, Agren H, Bertilsson L: **Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.** *European journal of clinical pharmacology* 2004, **59**(11):803-807.
104. Keers R, Uher R, Huezio-Diaz P, Smith R, Jaffee S, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W *et al*: **Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.** *The pharmacogenomics journal* 2011, **11**(2):138-145.
105. Khan A, Joyce M, Atkinson S, Eggen I, Baldytcheva I, Eriksson H: **A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.** *Journal of clinical psychopharmacology* 2011, **31**(4):418-428.

106. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J: **Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.** *Journal of clinical psychopharmacology* 2004, **24**(6):647-652.
107. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H *et al*: **HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.** *Neuromolecular medicine* 2010, **12**(3):237-242.
108. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ: **Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.** *Journal of clinical psychopharmacology* 2002, **22**(3):257-262.
109. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM: **Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.** *Primary care companion to the Journal of clinical psychiatry* 2007, **9**(2):100-107.
110. Lader M, Scotto JC: **A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder.** *Psychopharmacology* 1998, **139**(4):402-406.
111. LaLonde CD, Van Lieshout RJ: **Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis.** *Journal of clinical psychopharmacology* 2011, **31**(3):326-333.
112. Lanza FL, Chan FK, Quigley EM: **Guidelines for prevention of NSAID-related ulcer complications.** *The American journal of gastroenterology* 2009, **104**(3):728-738.
113. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ *et al*: **The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.** *Biological psychiatry* 2008, **63**(12):1103-1110.
114. Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF, 3rd: **Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial.** *The American journal of psychiatry* 2005, **162**(1):146-150.
115. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J: **Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.** *Pharmacogenetics* 1999, **9**(4):435-443.
116. Liebowitz MR, Gelenberg AJ, Munjack D: **Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.** *Archives of general psychiatry* 2005, **62**(2):190-198.
117. Lilly USA LLC: **Prozac (fluoxetine).** In: *US Product Monograph*. Indianapolis, IN; 2017.
118. Lin XQ, Wang P, Cai WK, Xu GL, Yang M, Zhou MD, Sun M, He F, He GH: **The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis.** *Pharmacopsychiatry* 2019, **52**(5):222-231.

119. Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, Baumann P, Dahl ML: **Steady-state concentrations of mirtazapine, N-desmethyilmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.** *Clinical pharmacokinetics* 2009, **48**(1):63-70.
120. **Clinical and Research Information on Drug-Induced Liver Injury**
[\[https://www.ncbi.nlm.nih.gov/books/NBK547852\]](https://www.ncbi.nlm.nih.gov/books/NBK547852)
121. Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D: **Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study.** *The Journal of clinical psychiatry* 2002, **63**(11):1020-1027.
122. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT: **Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.** *The Journal of clinical psychiatry* 2010, **71**(11):1482-1487.
123. Lundbeck Canada Inc: **Celexa (citalopram).** In: *CA Product Monograph.* Montreal, QC; 2016.
124. Lundbeck Canada Inc: **Cipralext (escitalopram).** In: *CA Product Monograph.* Montreal, QC; 2016.
125. Maron E, Tammiste A, Kallassalu K, Eller T, Vasar V, Nutt DJ, Metspalu A: **Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.** *European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology* 2009, **19**(6):451-456.
126. McAlpine DE, O'Kane DJ, Black JL, Mrazek DA: **Cytochrome P450 2D6 genotype variation and venlafaxine dosage.** *Mayo Clinic proceedings* 2007, **82**(9):1065-1068.
127. McCormack J CB, Calissi P: **Dosage Adjustment in Renal Impairment.** In: *Therapeutics.* Ottawa, ON: Canadian Pharmacists Association; 2018.
128. McLeod DR, Hoehn-Saric R, Porges SW, Zimmerli WD: **Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder.** *Psychopharmacology* 1992, **107**(4):535-540.
129. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M *et al*: **Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.** *American journal of human genetics* 2006, **78**(5):804-814.
130. Merideth C, Cutler AJ, She F, Eriksson H: **Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.** *International clinical psychopharmacology* 2012, **27**(1):40-54.
131. Mezhebovsky I, Magi K, She F, Datto C, Eriksson H: **Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.** *International journal of geriatric psychiatry* 2013, **28**(6):615-625.

132. Min W, Li T, Ma X, Li Z, Yu T, Gao D, Zhang B, Yun Y, Sun X: **Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.** *Psychopharmacology* 2009, **205**(3):409-417.
133. Mokhber N, Azarpazhooh MR, Khajehdaluae M, Velayati A, Hopwood M: **Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder.** *Psychiatry and clinical neurosciences* 2010, **64**(2):128-133.
134. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA *et al*: **SLC6A4 variation and citalopram response.** *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2009, **150B**(3):341-351.
135. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM: **CYP2C19 variation and citalopram response.** *Pharmacogenetics and genomics* 2011, **21**(1):1-9.
136. Muller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, Lieberman JA, Kennedy JL, Richter MA: **The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.** *Genetic testing and molecular biomarkers* 2012, **16**(8):897-903.
137. Murphy GM, Jr., Kremer C, Rodrigues HE, Schatzberg AF: **Pharmacogenetics of antidepressant medication intolerance.** *The American journal of psychiatry* 2003, **160**(10):1830-1835.
138. Nagler EV, Webster AC, Vanholder R, Zoccali C: **Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2012, **27**(10):3736-3745.
139. National Collaborating Centre for Mental Health (Great Britain), National Institute for Health and Clinical Excellence (Great Britain), British Psychological Society., Royal College of Psychiatrists., National Library of Medicine.: **Generalised anxiety disorder in adults management in primary, secondary and community care [Clinical guideline 113].** In. London: British Psychological Society : Royal College of Psychiatrists,; 2011.
140. National Collaborating Centre for Mental Health (Great Britain), National Library of Medicine.: **Social anxiety disorder recognition, assessment and treatment [Clinical guideline 159].** In. Leicester: The British Psychological Society,; 2013.
141. Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I: **Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.** *Human psychopharmacology* 2013, **28**(5):516-522.
142. Niitsu T, Fabbri C, Bentini F, Serretti A: **Pharmacogenetics in major depression: a comprehensive meta-analysis.** *Progress in neuro-psychopharmacology & biological psychiatry* 2013, **45**:183-194.

143. Nishimura M, Ueda M, Saruwatari J, Nakashima H, Ogusu N, Aoki A, Tsuchimine S, Matsuda K, Iwashita K, Ono T *et al*: **Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.** *Pharmacogenetics and genomics* 2016, **26**(9):403-413.
144. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, Linotte S, Mendlewicz J, Montgomery S, Snyder L *et al*: **5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.** *International clinical psychopharmacology* 2010, **25**(4):228-231.
145. Norton PJ, Price EC: **A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders.** *The Journal of nervous and mental disease* 2007, **195**(6):521-531.
146. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H: **CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.** *European journal of clinical pharmacology* 2003, **58**(10):659-661.
147. Oka Y, Okamoto K, Kawashita N, Shirakuni Y, Takagi T: **Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs.** *Biological & pharmaceutical bulletin* 2014, **37**(6):947-953.
148. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: **Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.** *The American journal of psychiatry* 2007, **164**(8):1181-1188.
149. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM: **Treatment of social phobia with gabapentin: a placebo-controlled study.** *Journal of clinical psychopharmacology* 1999, **19**(4):341-348.
150. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M *et al*: **Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.** *Journal of clinical psychopharmacology* 2004, **24**(2):141-149.
151. Parke-Davis Div of Pfizer Inc: **Lyrica (pregabalin).** In: *US Product Monograph*. NY, NY; 2018.
152. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP: **Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response.** *Pharmacogenetics and genomics* 2009, **19**(1):1-10.
153. Pfizer Canada Inc: **Zoloft (sertraline).** In: *CA Product Monograph*. Kirkland, QC; 2018.
154. Pfizer Canada Inc: **Effexor XR (venlafaxine).** In: *CA Product Monograph*. Kirkland, QC; 2018.
155. Pfizer Canada ULC: **Lyrica (pregabalin).** In: *CA Product Monograph*. Kirkland, QC; 2019.
156. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW: **Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder.** *Journal of psychopharmacology (Oxford, England)* 2003, **17**(3):276-282.

157. Pollack M, Mangano R, Entsuah R, Tzani E, Simon NM, Zhang Y: **A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.** *Psychopharmacology* 2007, **194**(2):233-242.
158. Poweleit EA, Aldrich SL, Martin LJ, Hahn D, Strawn JR, Ramsey LB: **Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders.** *Journal of child and adolescent psychopharmacology* 2019, **29**(5):348-361.
159. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: **Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.** *Journal of clinical psychopharmacology* 2009, **29**(1):39-43.
160. Pu M, Zhang Z, Xu Z, Shi Y, Geng L, Yuan Y, Zhang X, Reynolds GP: **Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.** *Pharmacogenomics* 2013, **14**(3):277-288.
161. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW: **Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study.** *Cephalalgia: an international journal of headache* 1999, **19**(7):668-675.
162. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH: **Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects.** *Clinical pharmacology and therapeutics* 1999, **66**(6):642-646.
163. Regier L, Jensen B: **Anxiety disorder medication.** In: *RxFiles drug comparison charts*. Saskatoon, SK: Saskatoon Health Region; 2018.
164. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F: **Mirtazapine versus fluoxetine in the treatment of panic disorder.** *Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas* 2001, **34**(10):1303-1307.
165. Rickels K, Downing R, Schweizer E, Hassman H: **Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.** *Archives of general psychiatry* 1993, **50**(11):884-895.
166. Roerig Div of Pfizer Inc: **Zoloft (sertraline).** In: *US Product Monograph*. NY, NY; 2016.
167. Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P: **Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?** *Depression and anxiety* 2011, **28**(7):560-567.
168. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J: **Prevention of NSAID-induced gastroduodenal ulcers.** *The Cochrane database of systematic reviews* 2002(4):Cd002296.
169. Rotberg B, Kronenberg S, Carmel M, Frisch A, Brent D, Zalsman G, Apter A, Weizman A: **Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-**

- 703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders.** *Journal of child and adolescent psychopharmacology* 2013, **23**(2):117-122.
170. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C: **Escitalopram versus citalopram: the surprising role of the R-enantiomer.** *Psychopharmacology* 2004, **174**(2):163-176.
171. Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G: **Mirtazapine in the treatment of panic disorder: an open-label trial.** *International clinical psychopharmacology* 2003, **18**(1):35-38.
172. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: **CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.** *Journal of clinical pharmacy and therapeutics* 2006, **31**(5):493-502.
173. Shapiro RE, Tepper SJ: **The serotonin syndrome, triptans, and the potential for drug-drug interactions.** *Headache* 2007, **47**(2):266-269.
174. Shiroma PR, Drews MS, Geske JR, Mrazek DA: **SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.** *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry* 2014, **22**(11):1140-1148.
175. Smith DA, Cleary EW, Watkins S, Huffman CS, Polvino WJ: **Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.** *International journal of clinical pharmacology and therapeutics* 1998, **36**(6):301-305.
176. Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R: **The major fluvoxamine metabolite in urine is formed by CYP2D6.** *European journal of clinical pharmacology* 2001, **57**(9):653-658.
177. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B: **Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.** *The American journal of psychiatry* 1999, **156**(5):756-760.
178. Stein DJ, Ipser JC, Balkom AJ: **Pharmacotherapy for social phobia.** *The Cochrane database of systematic reviews* 2004(4):CD001206.
179. Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, Souery D, Zobel A, Dernovsek MZ, Streit F *et al*: **Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2011, **12**(7):528-538.
180. Suzuki Y, Sawamura K, Someya T: **Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2006, **31**(4):825-831.
181. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Inoue Y, Ozdemir V, Someya T: **CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese**

- psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.** *Journal of psychopharmacology (Oxford, England)* 2011, **25**(7):908-914.
182. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
183. Swinson R: **Anxiety Disorders.** In: *RxTx.* Ottawa, ON: Canadian Pharmacists Association,; 2017.
184. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD: **Use of proton pump inhibitors and risk of osteoporosis-related fractures.** *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2008, **179**(4):319-326.
185. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J: **Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding.** *The American journal of gastroenterology* 2009, **104**(6):1475-1482.
186. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, Whitaker HJ, Farrington CP, Card TR, West J: **Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?** *Alimentary pharmacology & therapeutics* 2005, **22**(3):175-181.
187. Tepper SJ: **Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice.** *Headache* 2012, **52**(2):195-197.
188. Valeant Canada LP: **Manerix (moclobemide).** In: *CA Product Monograph.* Laval, QC; 2015.
189. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE: **Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.** *Therapeutic drug monitoring* 2005, **27**(4):478-483.
190. Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL: **Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.** *International journal of psychiatry in clinical practice* 2009, **13**(1):345-348.
191. van Vliet IM, den Boer JA, Westenberg HG: **Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine.** *Psychopharmacology* 1994, **115**(1-2):128-134.
192. Veefkind AH, Haffmans PM, Hoencamp E: **Venlafaxine serum levels and CYP2D6 genotype.** *Therapeutic drug monitoring* 2000, **22**(2):202-208.
193. Viikki M, Huuhka K, Leinonen E, Illi A, Setälä-Soikkeli E, Huuhka M, Mononen N, Lehtimäki T, Kampman O: **Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD.** *Neuroscience letters* 2011, **501**(1):20-24.
194. Waade RB, Hermann M, Moe HL, Molden E: **Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.** *European journal of clinical pharmacology* 2014, **70**(8):933-940.

195. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH: **Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.** *Clinical pharmacology and therapeutics* 2001, **70**(1):42-47.
196. Watanabe J, Suzuki Y, Fukui N, Sugai T, Ono S, Inoue Y, Someya T: **Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.** *Therapeutic drug monitoring* 2008, **30**(6):705-708.
197. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM: **A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.** *Journal of clinical psychopharmacology* 2004, **24**(1):49-55.
198. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S *et al*: **Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.** *Jama* 2015, **313**(24):2456-2473.
199. Wyeth Pharmaceuticals Inc: **Effexor XR (venlafaxine).** In: *US Product Monograph*. Philadelphia, PA; 2018.
200. Yevtushenko OO, Oros MM, Reynolds GP: **Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism.** *Journal of affective disorders* 2010, **123**(1-3):308-311.
201. Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA: **Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.** *Pharmacogenomics and personalized medicine* 2018, **11**:113-119.
202. Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, Huang F, Su H: **Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders.** *Neuroscience letters* 2010, **484**(1):56-61.